Andjelka Stones/Pinterest
Jun 5, 2026, 15:53
Andjelka Stones: Key Findings on Hemophilia A Gene Therapy
Andjelka Stones, Former Distinguished Adjunct Professor at NorthCentral University, shared a post on LinkedIn:
“Hemophilia A Gene Therapy
Gene therapy for hemophilia A: 4‑year data from the Phase 3 GENEr8‑1 trial are out.
Key findings (n=134):
- Mean treated bleed rate 82.6% from baseline
- Factor VIII infusion rate 95.5%
- 73.6% of patients had zero treated bleeds in year 4
- Mean FVIII activity at year 4: 16.1 IU/dL
- Only 18% of patients resumed prophylaxis
No new safety signals were observed. Health‑related quality of life remained improved.
This is the longest and largest Phase 3 follow‑up of a gene therapy in hemophilia.
Durable benefit after a single infusion.
Full citation in my archive.”
Stay updated with Hemostasis Today.
-
Sep 18, 2026, 06:48Gopal Patidar: Honoured to Contribute to the ASFA 2026 Guidelines for Therapeutic Apheresis
-
Sep 18, 2026, 05:48Julie Taylor: Navigating Tech Glitches to Deliver Engaging BBTS Presentation
-
Sep 18, 2026, 05:42Emma Copperwaite: BBTS Conference Presentation Highlights Power of Peer Support and Pushing Past Fear
-
Sep 18, 2026, 05:34Suhasini Sil: RGSSH Joins Mega Blood Donation Camp at Thyagaraj Stadium
-
Sep 18, 2026, 05:25Lisa Laun: Spleen Clears Activated Platelets to Limit Thrombosis and Inflammation
-
Sep 18, 2026, 05:16Louise St. Germain Bannon: ISTH Advocates for Enhanced Patient Safety in Blood Disorder Care
-
Sep 18, 2026, 05:08Vikas Veer: Exploring Sickle Cell Anemia at the Molecular Level
-
Sep 18, 2026, 01:35Matthew Hazell: From Platelet Refractoriness to Protecting Transplanted Organs
-
Sep 18, 2026, 01:23Apple Joy A. Valenzuela: Exploring How Neutrophil Develops from the Myeloblast to the Mature Segmented Neutrophil